-
Identifying Genes That Can Predict if Breast Cancer Drug Is Working
Share this:
Adding the drug trastuzumab to chemotherapy prevents cancer recurrence and improves survival in a majority of women with early stage HER2-positive breast cancer. But trastuzumab does not stop tumors from returning in about 25 percent of patients — and oncologists haven’t been able to identify these women before treatment. This situation may soon change, according to a Mayo Clinic study being presented this week at the 2012 CTRC-AACR San Antonio Breast Cancer Symposium.
EMBARGOED news release: Dr. Perez
Sound bites with Edith Perez, M.D., are available in the downloads below
Expert title for broadcast cg: Dr. Edith Perez, Mayo Clinic Oncologist
Share this:
Related articles
National Influenza Vaccination Week will be observed Dec. 4–8, which makes this a good time to learn more about the flu and why it's especially important ...
When David Elder’s back started to hurt in the fall of 2022, he thought his recurrent spasms had returned. But when medication didn’t help like ...
When Joanina Gicobi began her Ph.D. degree five years ago at Mayo Clinic Graduate School of Biomedical Sciences, she was interested in thinking creatively about ways ...